​

Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNA Stock Forecast

Avidity Biosciences (RNA) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $54.50, with a high of $59.00 and a low of $50.00. This represents a 104.43% increase from the last price of $26.66.

$5 $16 $27 $38 $49 $60 High: $59 Avg: $54.5 Low: $50 Last Closed Price: $26.66

RNA Stock Rating

Avidity Biosciences stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 15 Buy (83.33%), 2 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 2 15 1 Strong Sell Sell Hold Buy Strong Buy

RNA Price Target Upside V Benchmarks

TypeNameUpside
StockAvidity Biosciences104.43%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$54.50
Last Closing Price$26.66$26.66$26.66
Upside/Downside--104.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2558---13
Mar, 2547---11
Feb, 2547---11
Jan, 2547---11
Dec, 2448---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024Corinne JohnsonGoldman Sachs$59.00$43.5035.63%121.31%
Jun 12, 2024Yanan ZhuWells Fargo$50.00$28.9272.89%87.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankOutperforminitialise
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 21, 2024NeedhamBuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 03, 2024Goldman SachsBuyBuyhold
Sep 24, 2024Goldman SachsBuyinitialise
Sep 16, 2024Evercore PartnersUnderperformUnderperformhold
Aug 28, 2024BarclaysOverweightinitialise
Aug 12, 2024NeedhamBuyBuyhold
Jun 25, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.83$-3.24$-2.91$-2.89----
Avg Forecast$-1.80$-2.73$-3.36$-2.65$-2.87$-3.30$-3.57$-1.85$1.53
High Forecast$-1.39$-2.11$-2.07$-1.86$-2.70$-2.45$-2.17$-0.03$2.24
Low Forecast$-2.20$-3.34$-4.83$-2.98$-2.99$-4.49$-4.63$-3.20$0.81
Surprise %12.78%3.66%-3.57%9.81%0.70%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.79M$9.33M$9.22M$9.56M$10.90M----
Avg Forecast$5.47M$9.51M$8.32M$19.58M$9.74M$7.11M$21.89M$307.80M$861.96M
High Forecast$6.42M$11.16M$11.13M$46.62M$12.09M$9.67M$22.88M$418.75M$1.17B
Low Forecast$4.53M$7.87M$5.87M$5.92M$7.46M$4.54M$20.90M$196.62M$550.63M
Surprise %23.96%-1.98%10.84%-51.17%11.87%----

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.98M$-117.37M$-169.08M$-212.22M$-322.30M----
Avg Forecast$-131.18M$-199.05M$-245.03M$-212.22M$-207.69M$-253.46M$-248.49M$-118.09M$111.56M
High Forecast$-101.73M$-154.36M$-151.35M$-136.14M$-197.17M$-179.08M$-158.64M$-2.51M$163.85M
Low Forecast$-160.58M$-243.66M$-352.61M$-217.24M$-218.20M$-327.84M$-338.34M$-233.67M$59.18M
Surprise %-66.47%-41.03%-31.00%-55.19%----

RNA Forecast FAQ

Is Avidity Biosciences stock a buy?

Avidity Biosciences stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 15 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Avidity Biosciences is a favorable investment for most analysts.

What is Avidity Biosciences's price target?

Avidity Biosciences's price target, set by 18 Wall Street analysts, averages $54.5 over the next 12 months. The price target range spans from $50 at the low end to $59 at the high end, suggesting a potential 104.43% change from the previous closing price of $26.66.

How does Avidity Biosciences stock forecast compare to its benchmarks?

Avidity Biosciences's stock forecast shows a 104.43% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Avidity Biosciences over the past three months?

  • April 2025: 38.46% Strong Buy, 61.54% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Avidity Biosciences’s EPS forecast?

Avidity Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.3, marking a 14.19% increase from the reported $-2.89 in 2024. Estimates for the following years are $-3.57 in 2026, $-1.85 in 2027, and $1.53 in 2028.

What is Avidity Biosciences’s revenue forecast?

Avidity Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $7.11M, reflecting a -34.79% decrease from the reported $10.9M in 2024. The forecast for 2026 is $21.89M, followed by $307.8M for 2027, and $861.96M for 2028.

What is Avidity Biosciences’s net income forecast?

Avidity Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-253M, representing a -21.36% decrease from the reported $-322M in 2024. Projections indicate $-248M in 2026, $-118M in 2027, and $111.56M in 2028.